Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC October 31, 2023
FDA approves LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) October 31, 2023
FDA Approves KEYTRUDA for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemo as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery October 25, 2023
European Commission Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemo October 25, 2023
EC Approves ADCETRIS + AVD combo for Adult Patients with 1L CD30+ Stage III Hodgkin Lymphoma October 25, 2023
FDA Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma October 25, 2023
European Commission Approves Enrylaze for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma October 3, 2023
MHLW approves Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer October 3, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
European Commission Approves ORSERDU in Patients with ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer September 26, 2023
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
European Commission Approves KEYTRUDA + Trastuzumab and Chemo as 1L Treatment for HER2-Positive Advanced GEJ Adenocarcinoma Expressing PD-L1 September 6, 2023
Lynparza + abiraterone approved in Japan for the treatment of BRCA-mutated metastatic CRPC September 1, 2023
FDA Approves TALVEY™ (talquetamab-tgvs) for the Treatment of Patients with Heavily Pretreated Multiple Myeloma August 16, 2023
FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate) for Treatment of Patients with BRCA+ve metastatic CRPC August 16, 2023
European Commission Approves LONSURF® (Trifluridine/tipiracil) in Combination With Bevacizumab in 3rd Line Refractory mCRC August 9, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML July 27, 2023
